-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Mn9wpezN26874JptB9lUV9j2X1o0KKeYoeOvNm2ntz8HDGukyYifXdteLEoWmUKE
 Qs/0d/FQeAdr3BmM0Fyo6w==

<SEC-DOCUMENT>0001297077-09-000002.txt : 20090120
<SEC-HEADER>0001297077-09-000002.hdr.sgml : 20090119
<ACCEPTANCE-DATETIME>20090120173022
ACCESSION NUMBER:		0001297077-09-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090120
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
FILED AS OF DATE:		20090120
DATE AS OF CHANGE:		20090120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		09535004

	BUSINESS ADDRESS:	
		STREET 1:		2200 WILSON BLVD
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-0400

	MAIL ADDRESS:	
		STREET 1:		2200 WILSON BLVD.
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>jan2009_8k.htm
<DESCRIPTION>01/20/2009 8-K
<TEXT>
<html>
<head><meta content="text/html; charset=">
<title> </title>
</head>

<body >
<ul>
</ul>

<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">WASHINGTON, D.C.  20549</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>_________________________</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="4"><b>FORM 8-K</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>THE SECURITIES EXCHANGE ACT OF
1934</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Date of report (Date of earliest event reported):  <b>January 6,
2009</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="4"><b>CHAMPIONS BIOTECHNOLOGY, INC.</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Exact name of registrant as specified in its
charter)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="230.666609" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>Delaware</b></font></p align="center">
</td>
<td width="235.999941" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>0-17263</b></font></p align="center">
</td>
<td width="169.333291" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>52-1401755</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="230.666609" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(State or Other Jurisdiction</font></p align="center">
</td>
<td width="235.999941" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Commission File Number)</font></p align="center">
</td>
<td width="169.333291" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(IRS Employer</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="230.666609" colspan="1" rowspan="1" >
<p align="center">
<font size="2">of Incorporation)</font></p align="center">
</td>
<td width="235.999941" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="169.333291" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Identification No.)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">1400 North 14th Street, Arlington, Virginia
22209</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Address of Principal Executive
Offices)</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Registrant&#8217;s telephone number, including area code:
<b>(410) 630-1313</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Inapplicable</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Former Name or Former Address if Changed Since Last Report)
</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">&#8301;</font></p>
</td>
<td width="599.999850" colspan="1" rowspan="1" >
<p>
<font size="2">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</font></p>
</td>
</tr>
<tr valign="top">
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">&#8301;</font></p>
</td>
<td width="599.999850" colspan="1" rowspan="1" >
<p>
<font size="2">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</font></p>
</td>
</tr>
<tr valign="top">
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">&#8301;</font></p>
</td>
<td width="599.999850" colspan="1" rowspan="1" >
<p>
<font size="2">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</font></p>
</td>
</tr>
<tr valign="top">
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">&#8301;</font></p>
</td>
<td width="599.999850" colspan="1" rowspan="1" >
<p>
<font size="2">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center" style="border-bottom:double">
<font size="2">&nbsp;</font></p>
</td>
</tr>
</table></div>
<p align="center">
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>INFORMATION TO BE INCLUDED IN THE
REPORT</b></font></p align="center">
</td>
</tr>
</table></div>
<p align="center">
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="67.999983" colspan="1" rowspan="1" >
<p>
<a name="node13"></a><font size="2"><b>Item 5.02.</b></font></p>
</td>
<td width="567.999858" colspan="1" rowspan="1" >
<p>
<font size="2"><b>Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.</b></font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="2" rowspan="1" >
<p>
<font size="2">    &nbsp;On January 20, 2009, Champions Biotechnology, Inc. (the
&#8220;<b>Company</b>&#8221;) announced the January 19, 2009 appointment of Mark
Schonau, age 52, as Chief Financial Officer effective January 19,
2009.</font></p>
</td>
</tr>
<tr valign="top">
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="2" rowspan="1" >
<p>
<font size="2">    &nbsp; Under the terms of Mr. Schonau&#8217;s employment, Mr.
Schonau will receive an annual base salary of $185,000, plus benefits.  In
addition, he is eligible to participate in the Company&#8217;s Executive
Incentive Plan pursuant to which Mr. Schonau will be eligible to receive (for
the Company&#8217;s fiscal year 2009) up to 20% of his annual base salary paid
in cash, stock or stock options, or any combination thereof, in the
Company&#8217;s sole discretion, as well as receive a Restricted Stock Unit
grant of up to 35,000 shares, based on his meeting pre-determined performance
goals.  All amounts under the Company&#8217;s Executive Incentive Plan will be
prorated based on Mr. Schonau&#8217;s January 20, 2009 employment
date.</font></p>
</td>
</tr>
<tr valign="top">
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="2" rowspan="1" >
<p>
<font size="2">    &nbsp;In addition, upon Board approval, Mr. Sconau will
receive an option to purchase 233,000 shares of the Company&#8217;s common stock
under the terms of the Company&#8217;s 2008 Equity Incentive Plan, at an
exercise price equal to the market price of the shares on the date of grant.
The options will vest and be exercisable 33&#8531;% per year for each of Mr.
Schonau&#8217;s first full three years of employment.</font></p>
</td>
</tr>
<tr valign="top">
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="2" rowspan="1" >
<p>
<font size="2">    &nbsp;Mr. Schonau&#8217;s employment may be terminated by
either party at any time.  In the event Mr. Schonau&#8217;s employment is
involuntarily terminated by the Company without cause, he will receive a
severance payment equal to three months&#8217; base salary.</font></p>
</td>
</tr>
<tr valign="top">
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="2" rowspan="1" >
<p>
<font size="2">    &nbsp;The Company further announced that Durwood C. Settles,
who has been serving as the Company&#8217;s acting Chief Financial Officer, has
been appointed to the position of Controller.</font></p>
</td>
</tr>
<tr valign="top">
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="318.666587" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="2" rowspan="1" >
<p>
<font size="2">    &nbsp;A copy of the Company&#8217;s press release announcing
the appointments is attached hereto as Exhibit&nbsp;99.1.</font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="78.666647" colspan="1" rowspan="1" >
<p>
<font size="2"><b>Item 9.01.</b></font></p>
</td>
<td width="558.666527" colspan="1" rowspan="1" >
<p>
<font size="2"><b>Financial Statements and Exhibits.</b></font></p>
</td>
</tr>
<tr valign="top">
<td width="78.666647" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="558.666527" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="78.666647" colspan="1" rowspan="1" >
<p align="right">
<font size="2"><i>(d)</i></font></p align="right">
</td>
<td width="558.666527" colspan="1" rowspan="1" >
<p>
<font size="2"><i>Exhibits</i></font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">The following exhibits are filed herewith:</font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><u>Exhibit No.</u></font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press
Release dated January 20, 2009</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>SIGNATURES</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">    &nbsp;Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>CHAMPIONS BIOTECHNOLOGY, INC.</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Registrant)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="191.999952" colspan="1" rowspan="1" >
<p>
<font size="2">Date: January 20, 2009</font></p>
</td>
<td width="35.999991" colspan="1" rowspan="1" >
<p>
<font size="2">By:</font></p>
</td>
<td width="407.999898" colspan="1" rowspan="1" >
<p>
<font size="2"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Douglas D.
Burkett        &nbsp;&nbsp;</u></font></p>
</td>
</tr>
<tr valign="top">
<td width="191.999952" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="35.999991" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="407.999898" colspan="1" rowspan="1" >
<p>
<font size="2">Douglas D. Burkett</font></p>
</td>
</tr>
<tr valign="top">
<td width="191.999952" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="35.999991" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="407.999898" colspan="1" rowspan="1" >
<p>
<font size="2">President</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center" style="border-bottom:double">
<font size="2">&nbsp;</font></p>
</td>
</tr>
</table></div>
<p>
</p align="right">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="635.999841" colspan="1" rowspan="1" >
<p align="right">
<font size="2"><b><u>Exhibit 99.1</u></b></font></p align="right">
</td>
</tr>
<tr valign="top">
<td width="635.999841" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="635.999841" colspan="1" rowspan="1" >
<p>
<font face="Arial" size="4">Champions Biotechnology, Inc.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NEWS</font></p>
</td>
</tr>
<tr valign="top">
<td width="635.999841" colspan="1" rowspan="1" >
<p align="center">
<font face="Arial" size="2">1400 North 14<sup>th</sup> Street, Arlington,
Virginia 22209 USA. Tel. 410-630-1313</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="635.999841" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="635.999841" colspan="1" rowspan="1" >
<p>
<font face="Arial" size="2">For Immediate Release </font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>Champions Biotechnology, Inc. Appoints Three Key Executives to
Management Team</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><b><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
Hires Mark Schonau as Chief Financial Officer; Sara Parkerson, RN, MSN, OCN, CCM
as Director of Personalized Oncology Services US; and Elizabeth Bruckheimer, PhD
as Director of Preclinical Development</i></b></font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">January 20, 2009 - Champions Biotechnology, Inc. (OTC Bulletin
Board: CSBR), a company engaged in the development of advanced preclinical
platforms and tumor specific data to enhance the value of oncology drugs, has
appointed three key executives to the company&#8217;s management team. They are:
Mark Schonau as Chief Financial Officer; Sara Parkerson, RN, MSN, OCN, CCM as
Director of Personalized Oncology Services US; and Elizabeth Bruckheimer, PhD as
Director of Preclinical Development.  Durwood C. Settles, who had served as
acting CFO, has been named the company&#8217;s Controller.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">&#8220;The growth we are experiencing in all of our business
segments has mandated these additions to our team.  I am pleased to welcome
Mark, Sara and Beth to Champions,&#8221; said Doug Burkett, PhD, President of
Champions Biotechnology, Inc.  &#8220;The breadth of their experience is a
testament to the good work we are doing at Champions.  Each of these individuals
brings tremendous expertise to the leadership roles they will
undertake.&#8221;</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><b>Mark Schonau  </b>brings more than twenty-five years of
leadership in financial and operations management to Champions and will serve as
Chief Financial Officer.  Mr. Schonau previously served as Chief Financial
Officer for Insys Therapeutics a development stage biopharmaceutical company
focused on discovering, developing, and commercializing products to address
cancer-related pain and CINV.  Prior to that, Mr. Schonau served as CFO of
Axway, Inc., a leading global provider of collaborative business solutions from
January 2006 through August 2007.  From January 2001 to January 2006, Mr.
Schonau served as CFO and Senior Vice President of Administration for Cyclone
Commerce, a business-to-business systems provider that was acquired by Axway in
2006.  Upon Cyclone&#8217;s acquisition by Axway, Mr. Schonau became the North
American Chief Financial Officer of the surviving entity.  From 1988 to 2000,
Mr. Schonau also served as CFO for two public companies; Viasoft (NASDQ - VIAS)
and CyCare (NYSE - CYS).  Mr. Schonau was also employed by the accounting firm
of Ernst &amp; Young LLP from January 1981 to May 1988.  He is a member of the
Arizona and American Institutes of Certified Public Accountants and currently
sits on the board of directors of the Arizona Technology Council.  Mr. Schonau
received a Bachelors degree in Accounting from Arizona State
University.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><b>Sara Parkerson, RN, MSN, OCN, CCM,</b> is an oncology nurse
with not only a strong clinical background, but also a solid foundation in
business, disease management operations, case management, and health care
consulting.  Ms. Parkerson is running daily operations for Champions&#8217;
Personalized Oncology services; a role in which she is working directly with
patients and doctors. </font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">Prior to joining Champions, Ms. Parkerson was Vice President of
Oncology Services for Matria Healthcare.  Ms. Parkerson was responsible for
development of new clinical products and services for the oncology program,
covering the full continuum of cancer care.  Previously, she was in the role of
Director of Oncology Case Management Operations starting in 2002.  Prior to
joining Matria, Ms. Parkerson worked in healthcare consulting with Cap Gemini
Ernst &amp; Young from 1997 to 2002, a role that included projects involving
care management operations, design, and implementation of clinical information
systems, process redesign, and cancer program evaluation.  She has over 25 years
of oncology nursing experience and holds a Masters degree in Nursing from
Catholic University of America and a Bachelors degree in Nursing from American
University.  She is an Oncology Certified Nurse and a Certified Case Manager.
</font></p>
</td>
</tr>
</table></div>
<p>
</p>
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><b>Elizabeth Bruckheimer, PhD,</b> is a cancer biologist and
pharmacologist with a strong scientific and managerial background in preclinical
and translational science and cancer drug development in both academic and
industry settings.  Dr. Bruckheimer will manage the day-to-day operations of the
Champions&#8217; Preclinical Platform and Preclinical eValuation programs.  She
will also support the internal drug development programs and the Personalized
Oncology programs at Champions.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">Prior to joining Champions, Dr. Bruckheimer was Associate
Director &amp; Manager at Systems Medicine, LLC from 2007 to 2008 where she led
preclinical and translational research programs.  From 2003 to 2007, Dr.
Bruckheimer was a Senior Scientist in cancer biology, at MedImmune, Inc., where
she was involved in several preclinical and translational programs focused on
monoclonal antibodies, cancer vaccines, and small molecule technologies for the
treatment of cancer.  From 2001 to 2003, Dr. Bruckheimer was a Scientist II, at
Targeted Genetics Corporation, involved in gene therapy programs aimed at
treating cancer, cystic fibrosis, hemophilia, and AIDS.  Dr. Bruckheimer holds a
Bachelors degree in Biochemistry from the University of Arizona and a Doctorate
in Biomedical Sciences from the University of Texas M.D. Anderson Cancer
Center.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"> For more information regarding Champions Biotechnology&#8217;s
growing business and recent news, please visit
<u>www.championsbiotechnology.com</u>.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><b><u>About Champions Biotechnology, Inc. </u></b></font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">Champions Biotechnology, Inc. is engaged in the development of
advanced preclinical platforms and predictive tumor specific data to enhance and
accelerate the value of oncology drugs.  The Company&#8217;s Preclinical
Platform is a novel approach based upon the implantation of primary human tumors
in immune deficient mice followed by propagation of the resulting engraftments
(Biomerk Tumorgrafts&#8482;) in a manner that preserves the biological
characteristics of the original human tumor.  Early studies suggest that these
Tumorgrafts closely reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. </font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2">Champions Biotechnology leverages its preclinical platform to
evaluate drug candidates and to develop a portfolio of novel therapeutic
candidates through pre-clinical trials.  As drugs progress through this early
stage of development, the Company plans to sell, partner or license them to
pharmaceutical and/or biotechnology companies, as appropriate.  The Company also
offers its predictive preclinical platform and tumor specific data to physicians
for personalized patient care and to companies for evaluation of oncology drugs
in models that integrate prognostic testing with biomarker discovery.
</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><b><u>Forward-Looking Statements</u></b></font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p>
<font size="2"><i>This press release contains "forward-looking statements"
(within the meaning of the Private Securities Litigation Act of 1995) that
inherently involve risk and uncertainties. Champions Biotechnology generally
uses words such as "believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify forward-looking
statements. One should not place undue reliance on these forward-looking
statements.  The Company&#8217;s actual results could differ materially from
those anticipated in the forward-looking statements for many unforeseen factors.
See Champions Biotechnology&#8217;s Form 10-KSB for the fiscal year ended April
30, 2008 for a discussion of such risks, uncertainties and other factors.
Although the Company believes the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the date on which
the statements are made, and Champions Biotechnology&#8217;s future results,
levels of activity, performance or achievements, including but not limited to
the achievement of milestones as required to realize the royalties referenced
above, may not meet these expectations.  The Company does not intend to update
any of the forward-looking statements after the date of this press release to
conform these statements to actual results or to changes in Champions
Biotechnology&#8217;s expectations, except as required by law.</i></font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center" style="border-bottom:double">
<font size="2">&nbsp;</font></p>
</td>
</tr>
</table></div>
<p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
